The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Identifying risk factors for severe COVID-19 in patients with AML, MDS and ALL
In this video, Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York, NY, shares some results from an analysis which aimed to identify risk factors for severe COVID-19 infection in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). First, Dr Desai explains the data hub that was used, the ASH RC COVID-19 Registry for Hematology, and the methods of obtaining data for the analysis. Dr Desai then explains why mortality rates were higher in these patients, drawing focus on the risk factors that were associated with severe COVID-19 infection, including having neutropenia and active primary disease at diagnosis. To conclude, Dr Desai discusses plans to look at the more recent data in the registry, allowing for a comparison to be made between 2020 and 2021. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
